ArticleBioscience reports2026
Evaluation of correlations between serum and urinary vitamin D metabolites using LC-MS/MS.
Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin D (VD) is involved in bone health, immunity, cardiovascular function, and cancer prevention. Recent studies suggested the potential of 24,25-dihydroxyvitamin D3 [24,25(OH)2D3] and the VD metabolite ratio (VMR = [24,25(OH)2D3/25(OH)D] × 100) as indicators of VD levels. An assessment of VD levels relies on serum measurements. The present study investigated the utility of urinary VD metabolites as a non-invasive alternative and their potential as surrogate markers for serum VD metabolites. We used residual serum and urine from the annual health check-ups of employees at Shinshu University Hospital, Japan (n = 506). Urine samples were mixed with β-glucuronidase. Serum and urine were processed via solid-phase extraction, followed by DAP-PA derivatization. LC-MS/MS was used to quantify serum and urinary 25(OH)D3, 25(OH)D2, 3-epi-25(OH)D3, and 24,25(OH)2D3 and urinary 23,25(OH)2D3. Serum whole parathyroid hormone (PTH) levels were measured, and urinary VD metabolites were adjusted for urinary creatinine. We also investigated whether serum and urinary VD metabolites correlated with PTH. The results showed that urinary 24,25(OH)2D3 and 23,25(OH)2D3 strongly correlated with serum 25(OH)D [25(OH)D3 + 25(OH)D2] (all ρ >0.7, P<0.001). Urinary 24,25(OH)2D3, 23,25(OH)2D3, and VMR had stronger inverse correlations with whole PTH (ρ = -0.297, -0.274, -0.308, respectively; all P<0.001), whereas serum 25(OH)D showed a weak correlation (ρ = -0.174, P<0.001). In conclusion, urinary VD metabolites, particularly 24,25(OH)2D3, 23,25(OH)2D3 and the VMR, correlated with serum values and PTH, suggesting their potential as non-invasive markers for the VD status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.